CD8A and neoplasm: To assess the capacity of effector CD8+ T cells to respond to antigen restimulation in the TME, we adoptively transferred activated OT-I cells into B16-OVA tumour-bearing mice and assessed their activation in the TME (Extended Data Fig. 2e).